Cancer treatments have transformed patient outcomes, but one major challenge remains: treatment resistance.
In this video on OncoDaily TV, Dr. Elen Baloyan sits down with Dr. Lynda Chin, Co-founder & CEO of Apricity Health, National Academy of Medicine member and cancer genomic scientist, to discuss one of oncology’s biggest obstacles.
Dr. Chin explains why resistance, rather than the lack of effective first-line therapies, is now the greatest barrier to long-term cancer control. She introduces the concept of Perturbation Response Discovery, a new strategy that uses blood-based monitoring to detect resistance earlier than imaging and before it becomes clinically apparent, enabling dynamic, personalized combination therapies.
The conversation also explores Dr. Chin’s broader vision of “drugging health” – developing medicines designed not only to treat disease but to maintain resilience and prevent illness before it develops. From immunotherapy and precision oncology to GLP-1 therapies and the future of preventive medicine, this discussion offers an exciting look at where biomedical innovation is headed.